Skip to main content
. Author manuscript; available in PMC: 2016 Apr 15.
Published in final edited form as: Clin Cancer Res. 2015 Jun 17;21(20):4586–4596. doi: 10.1158/1078-0432.CCR-15-0584

Figure 1.

Figure 1

Figure 1

Monitoring of somatic genomic alterations in plasma during targeted therapy. Allele frequency (AF) of the identified mutations is represented on the left Y-axis while the sum of the target lesions on CT scan is represented on the right Y-axis. SD: stable disease according to RECIST criteria; PD: progressive disease. The colored box depicts the time on treatment. The second graph depicts the evolution of cfDNA concentration during this time frame in ng/ml of plasma. A. Patients with decreasing AF during therapy. B. Patients with increasing AF during therapy. C. Patients with mixed or discordant AF changes during therapy.